40019-21-4

Basic information

• Product Name: ETHYL 3-METHYL-1,2,4-OXADIAZOLE-5-CARBOXYLATE
• Synonyms: ETHYL 3-METHYL-1,2,4-OXADIAZOLE-5-CARBOXYLATE;3-Methyl-[1,2,4]oxadiazole-5-carboxylic acid ethyl ester
• CAS NO: 40019-21-4
• Molecular Formula: C₆H₈N₂O₃
• Molecular Weight: 156.14
• Mol File: 40019-21-4.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 238.0±23.0 °C(Predicted)
• Appearance: /
• Density: 1 +-.0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: -2.95±0.30(Predicted)
• CAS DataBase Reference: ETHYL 3-METHYL-1,2,4-OXADIAZOLE-5-CARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: ETHYL 3-METHYL-1,2,4-OXADIAZOLE-5-CARBOXYLATE(40019-21-4)
• EPA Substance Registry System: ETHYL 3-METHYL-1,2,4-OXADIAZOLE-5-CARBOXYLATE(40019-21-4)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 40019-21-4(Hazardous Substances Data)

Usage

General Description

ETHYL 3-METHYL-1,2,4-OXADIAZOLE-5-CARBOXYLATE is a chemical compound that belongs to the oxadiazole family. It is an organic ester with the molecular formula C6H7N3O3 and is commonly used in the pharmaceutical and agricultural industries. ETHYL 3-METHYL-1,2,4-OXADIAZOLE-5-CARBOXYLATE has potential applications in drug development and crop protection due to its unique chemical properties. It is often used as an intermediate in the synthesis of various pharmaceuticals and agrochemicals, making it an important building block in organic chemistry.ETHYL 3-METHYL-1,2,4-OXADIAZOLE-5-CARBOXYLATE is a chemical compound that belongs to the oxadiazole family. It is an organic ester with the molecular formula C6H7N3O3 and is commonly used in the pharmaceutical and agricultural industries. ETHYL 3-METHYL-1,2,4-OXADIAZOLE-5-CARBOXYLATE has potential applications in drug development and crop protection due to its unique chemical properties. It is often used as an intermediate in the synthesis of various pharmaceuticals and agrochemicals, making it an important building block in organic chemistry.

Upstream product

• 4755-77-5 Ethyl oxalyl chloride 
• 118493-85-9 acetamide oxime 
• 118493-85-9 N-hydroxyacetamidine 
• 22059-22-9 1-(hydroxyimino)ethylamine 

Downstream Products

• 944906-02-9 3-methyl-1,2,4-oxadiazole-5-carbaldehyde 
• 1380672-67-2 N-(2-chlorophenyl)-3-methyl-1,2,4-oxadiazole-5-carboxamide 
• 40019-29-2 3-methyl-1,2,4-oxadiazole-5-carbohydrazide 
• 112960-56-2 (3-methyl-1,2,4-oxadiazol-5-yl)methanol 

Relevant articles and documents

COMBINATION TREATMENTS COMPRISING ADMINISTRATION OF 1H-PYRAZOLO[4,3-B]PYRIDINES

The present invention provides 1H-pyrazolo[4,3-b]pyridin-7-amines of formula (I) as PDE1 inhibitors together with a second compound useful in the treatment of a neurodegenerative disorder and their combined use as a medicament, in particular for the treatment of neurodegenerative and/or cognitive disorders.

COMBINATION TREATMENTS COMPRISING ADMINISTRATION OF 1H-PYRAZOLO[4,3-B]PYRIDINES

The present invention provides 1H-pyrazolo[4,3-b]pyridin-7-amines of formula (I) as PDE1 inhibitors together with a second compound which compound is useful in the treatment of a psychiatric disorder and their combined use as a medicament, in particular for the treatment of psychiatric and/or cognitive disorders.

NOVEL CHIRAL N-ACYL-5,6,7,(8-SUBSTITUTED)-TETRAHYDRO-[1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR MEDIATED DISORDERS AND CHIRAL SYNTHESIS THEREOF

The present invention relates to novel compounds of Formula I and their use in therapeutic treatments. The invention further relates to a novel chiral synthesis of 5,6,7,(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines using N-sp3 protective groups. The invention also provides intermediates for use in the synthesis of compounds of Formula I.